ACI
TCRT icon

AMP Capital Investors’s Alaunos Therapeutics TCRT Stock Holding History

AMP Capital Investors’s Portfolio TCRT Stock Details TCRT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-70
Closed -$89K – 1235
2015
Q4 		$89K Buy
+70
New +$116K ﹤0.01% 1212
2013
Q4 		– Sell
-834
Closed -$453K – 1268
2013
Q3 		$453K Hold
834
– – ﹤0.01% 988
2013
Q2 		$288K Buy
+834
New +$232K ﹤0.01% 1206

Other funds holding TCRT

TS
Third Security Radford, Virginia $241M AUM 45.43% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MVP
Miller Value Partners Sarasota, Florida $383M AUM 38.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
MP
MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
BGA
Belmont Global Advisors Dallas, Texas $106M AUM 2.89% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

AMP Capital Investors's TCRT Position: Q1 2016 in Review

AMP Capital Investors sold out of Alaunos Therapeutics (TCRT) in Q1 2016, closing a stake of 70 shares — an estimated $89K sold.

AMP Capital Investors first reported a position in TCRT in Q2 2013 and held it in 3 quarters. The position peaked at $453K in Q3 2013. 143 funds tracked by Wall St. Rank hold TCRT as of Q1 2016.

  • AMP Capital Investors reported no remaining Alaunos Therapeutics position as of Q1 2016 after selling out during the quarter.
  • AMP Capital Investors sold 70 Alaunos Therapeutics shares in Q1 2016, an estimated $89K.
  • AMP Capital Investors first reported a position in Alaunos Therapeutics in Q2 2013 and held it in 3 quarters.
  • AMP Capital Investors's Alaunos Therapeutics position peaked at $453K in Q3 2013.
  • 143 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q1 2016.

Based on AMP Capital Investors's 13F filing for Q1 2016, filed 16 May 2016.